Use of D-Enantiomeric Peptides for the Therapy of Neuropathic Pain

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention relates to novel D-enantiomeric peptides that specifically inhibit the N-type voltage-gated calcium channel (Cav2.2) for the treatment of neuropathic pain. These peptides are designed to be orally administrable, highly stable in vivo, and non-immunogenic, addressing many of the shortcomings of existing therapies like Ziconotide (Prialt), which require invasive administration and are associated with significant side effects. The new peptides offer selective inhibition of Cav2.2 without affecting L-type calcium channels, reducing unwanted cardiovascular effects and making them suitable for long-term pain management.

Use CasesContent extracted from patent full text and abstract with AI.

• Oral medication for chronic neuropathic pain management, such as in diabetes-induced neuropathy or post-herpetic neuralgia.
• Alternative to opioid and current Cav2.2 inhibitors for cancer- or chemotherapy-induced neuropathic pain.
• Treatment option for patients with multiple sclerosis who develop neuropathic pain.
• Potential co-therapy to reduce opioid doses in refractory pain cases.
• Development of new classes of non-opioid analgesics for general chronic pain management.

BenefitsContent extracted from patent full text and abstract with AI.

• Oral administration possible, eliminating the need for invasive procedures (e.g., intrathecal injections).
• High stability against protease degradation, ensuring longer duration and potential for once-daily dosing.
• Non-immunogenic, reducing risk of immune-related adverse reactions.
• Highly selective inhibition of Cav2.2, minimizing off-target and cardiovascular side effects.
• Reversible inhibition reduces overdose risk compared to existing irreversible blockers.
• Lack of opioid-like addictive potential, contributing to safer long-term pain control.
• Potential for improved quality of life and reduced healthcare costs by addressing unmet needs in chronic neuropathic pain therapy.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 10, as well as to homologs, fragments or parts thereof.